RaQualia Pharma

Stock Market Tokyo Stock Exchange JASDAQ
Security Code 4579
Website RaQualia Pharma Website

Pipelines

Updated on 6 6, 2020

Completed
On planning
On going
Launch
Plan
Project Compound code
(Generic name)
Indication Partnered party Discovery Pre-Clin, Clinical Trial NDA Approval Launch Territory Remarks
Phase 1 Phase 2 Phase 3
PotassiumCompetitive acid blocker
(P-CAB)
RQ-00000004
(Tegoprazan)
CJ-12420 [HK inno.N]
LXI-15028 [Luoxin Pharma]
GERD
(ERD/NERD)
Gastric ulcer
H. pylori treatment
-
Completed P1
Japan
HK inno.N
Completed P1
USA
Launch (March 2019)
Korea Product name: K-CAB
Co-promotion with Chong Kun Dang Pharmaceutical Corp.
Blockbuster expectation with annual sales of 100 billion won.
On going P3
Launch
2021
China Re-contracted: HK inno.N => Luoxin Pharma
Market Size (China): 260 billion yen (2 billion 600 million USD) *Investigation of RaQualia
Preparation NDA
Launch
2021
Vietnam Re-contracted: HK inno.N => Vimedimex Medi-Pharma JSC
Related information
Preparation NDA
Launch
2022
Indonesia Re-contracted: HK inno.N => Kalbe Farma
Related information
Preparation NDA
Launch
2022
Thailand Re-contracted: HK inno.N => Pond's Chemical Thailand R.O.P.
Preparation NDA
Launch
2022 (Mexico)
Latin America
17 countries
(Mexico, Argentina etc.)
Re-contracted: HK inno.N => Laboratorios Carnot
Related information
Europe
ROW ROW: Latin America (Brazil etc.), East European, Middle East
Taiwan
Southeast Asia
CRHR2 antagonist RQ-00490721 Heart failure Nagoya University
(Collaborative Research)
On going
Japan Started an investigation of preclinical efficacy.
Presentation at AHA 2019.
This research plans to complete the research phase from the end of 2019 to 2020. [Reference]
TRPM8 blocker RQ-00434739 Neuropathic pain -
On planning
Japan
P2X7 receptor antagonist RQ-00466479
AKP-23494954 [Asahi Kasei Pharma]
Neuropathic pain Asahi Kasei Pharma Undisclosed Global Diabetic neuropathic medicine, herpes virus infective neuropathic medicine. [Reference]
Selective sodium channel blocker - Analgesia
Pruritus
Maruho Undisclosed Global
- Pain -
Discovery
Japan
Specific Ion Channels - Gastrointestinal Tract EA Pharma Undisclosed Global
Specific Ion Channels - - ASKA Pharmaceutical
(Collaborative Research)
On going
-
Sodium channel Nav1.7 selective blocker RQ-00488738 Pain - - Product of collaboration with XuanZhu Pharma
Protein-Protein Interaction Targets - Pain Interprotein
(Collaborative Research)
On going
-
Idiopathic childhood nephrotic syndrome therapy - Idiopathic childhood nephrotic syndrome Epigeneron
(Collaborative Research)
On going
- Utilize locus-specific chromatin immunoprecipitation (locus-specific ChIP).
5-HT4 partial agonist RQ-00000010 Gastroparesis
Functional dyspepsia
Chronic Constipation
-
Completed P1
UK Mosapride's sales amount of peak tops is 21.2 billion yen (Japan)
Gastroparesis -
Investigator Clinical Trial
USA Collaboration with Virginia Commonwealth University (VCU) Parkinson's and Movement Disorders Center
RQ-00000009
AAT-009 [AskAt]
Alzheimer's AskAt
(Global)
On planning P2
USA
5-HT2B antagonist RQ-00310941 IBS-D -
Completed P1
UK
Motilin receptor agonist RQ-00201894 Gastroparesis
Functional dyspepsia
Post - operative Ileus
-
On planning P1
Japan
Ghrelin receptor agonist RQ-00000005
(Capromorelin)
AT-002 [Elanco]
Weight loss, Anorexia: Dog Elanco Animal Health
(Global (Animal))
Launch (October 2017)
USA Product name: Entyce
Weight loss, Anorexia: Cat
Pivotal study
USA
RQ-00433412 Cancer-Related Anorexia/Cachexia Syndrome
Constipation resulting from Spinal Cord Injury
-
On planning
Japan
Ziprasidone RQ-00000003
(Ziprasidone Hydrochloride Monohydrate)
ME2112 [Meiji Seika Pharma]
Schizophrenia Meiji Seika Pharma
Completed P3 (Result: No significant difference)
Japan Market Size (Japan): 160 Billion Yen *Investigation of RaQualia
EP4 antagonist RQ-00000007
(Grapiprant)
AAT-007 [AskAt]
AT-001 [Elanco]
IK-007 [Ikena]
RMX1002 [RMX]
Osteoarthritis: Dog Elanco Animal Health
(Global (Animal))
Launch (USA: 2017, Europe: 2019, Brazil: 2020)
USA
Europe
Brazil
Product name: Galliprant
MSS Colorectal Cancer AskAt
(Global (Excluding animal))
USA Re-contracted: AskAt => Arrys Therapeutics (Global excluding China and Taiwan)
Development: Arrys parent company Ikena Oncology
Clinical study with grapiprant in combination with pembrolizumab(anti PD-1 antibody, KEYTRUDA).
NSCLC Adenocarcinoma
Cancer
On going P1
China Re-contracted: AskAt => Ningbo Tai Kang Medical Technology
Development: Ningbo NewBay Medical Technology
Pain
Completed P2a
USA
Completed P1
China Re-contracted: AskAt => RMX Biopharma
Development: A joint venture between Shanghai HaiHe Biopharma and China Shijiazhuang Holding Group [Reference]
RQ-00000008
AAT-008 [AskAt]
AT-019 [Elanco]
Osteoarthritis etc.
(Animal)
AskAt
(Global)
Started transferring the manufacturing process of the API and early formulation work (early-2019)
USA
Europe
Re-contracted: AskAt => Elanco
Cancer
On planning P1
USA Re-contracted: AskAt => Arrys Therapeutics (Global excluding China and Taiwan)
Development: Arrys parent company Ikena Oncology
On planning P1
China Re-contracted: AskAt => Ningbo NewBay Medical Technology
COX-2 Inhibitor RQ-00317076
AAT-076 [AskAt]
RMX1001 [RMX]
Pain AskAt
(Global)
Completed P2a
USA
On going P1
China Re-contracted: AskAt => RMX Biopharma
Development: A joint venture between Shanghai HaiHe Biopharma and China Shijiazhuang Holding Group [Reference]
On planning P1
Japan
CB2 receptor agonist RQ-00202730
AAT-730 [AskAt]
OCT461201 [OCT]
IBS AskAt
(Global)
On going
USA Re-contracted: AskAt => Oxford Cannabinoid Technologies (OCT) (Global excluding Japan)
Developmental status
IBD
Neuropathic pain
PoC
All potential indications
On going
Japan

Other Pipelines

Updated on 9 20, 2019

Project Indication Partnered party Territory Remarks
Dalbavancin MRSA Infections - Japan US product name: Dalvance
Anidulafungin Candida Infections - Japan US product name: Eraxis

Other Contracts

Updated on 12 15, 2018

Contractor Contract contents Remarks
H. Lundbeck A/S
(Denmark)
RaQualia Grants Patent License to H. Lundbeck Press release
Shire AG
(Swiss)
RaQualia Grants a Non-Exclusive Patent License to Shire AG For the Use of Ghrelin Receptor Agonist Press release
- RaQualia Pharma Joins DeNA & DeNA Life Science AI-Powered Drug Discovery Research Collaboration Press release

University Collaborative Research

Updated on 12 4, 2019

RaQualia Pharma Industry-Academia Collaborative Research Center

University Department Research theme Remarks
Nagoya University Department of Biochemistry, Graduate School of Medicine Search for selective inhibitors targeting specific enzymes for treatment of refractory neuroblastoma Press release
Department of Cardiology, Graduate School of Medicine Search for selective inhibitors targeting specific proteins for treatment of heart failure Press release
Department of Respiratory Medicine, Graduate School of Medicine Search for novel therapeutic agents for KRAS mutated lung cancer Press release
Department of Brain Function, Research Institute for Environmental Medicine Mass spectrometry imaging and characterization of TRPM8 blocker RQ-00434739 in the brain Press release
Department of Molecular Medicine and Metabolism, Research Institute of Environmental Medicine Characterization of the mechanism of action of a novel small molecule compound targeting non-alcoholic steatohepatitis (NASH) Press release
Nagoya City University Department of Biomedical Science, Graduate School of Pharmaceutical Sciences Discovery of novel small molecules for the treatment of Amyotrophic Lateral Sclerosis (ALS) Press release
Department of Bacteriology, Graduate School of Medical Sciences Search for novel therapeutic for macrolide-resistant group A streptococci Press release
Gifu Pharmaceutical University Molecular Pharmacology, Department of Biofunctional Evaluation Evaluation of efficacy of a specific compound on retinal vein occlusion (RVO) Press release

TMRC (subsidiary) Pipeline

Updated on 8 15, 2019

Completed
On planning
On going
Launch
Plan
Project Compound code
(Generic name)
Indication Partnered party Discovery Pre-Clin, Clinical Trial NDA Approval Launch Territory Remarks
Phase 1 Phase 2 Phase 3
TM-411 TM-411
(Tamibarotene)
SY-1425 [Syros Pharmaceuticals]
OP-09 [Ohara Pharmaceutical]
Newly diagnosed unfit AML Syros Pharmaceuticals
On going P2 (Multiple drug combination)
USA Combination with azacitidine.Initial data.
Relapsed or refractory AML
On going P2 (Multiple drug combination)
USA
Neuroblastoma
(NB)
Ohara Pharmaceutical
On going P1/2
Japan
Acute promyelocytic leukemia
(APL)
Toko Pharmaceutical Industrial
NDA
China
Neutropenia
(NP)
-
Completed
USA

Subsidiary

Updated on 4 24, 2019

Company name
TMRC Co., Ltd.
RaQualia Innovations Inc.

RaQualia Pharma Business Performance

※ Unit: million yen (Amounts are rounded down to the nearest million yen)
※ Non-consolidated: 2011, 2012, 2015, 2016 year. Consolidated: Other years.

Because of the personal survey, there are cases where the information on this site is "different from the fact" due to business content change or misunderstanding etc.
Therefore, please do not use for investment judgment. Also, this site is not intended to solicit investment.

Advertisements